Impact of Statin Use on Exercise-Induced Cardiac Troponin Elevations

• Published in: The American journal of cardiology 2014-08, Vol.114 (4), p.624-628
• Main Authors: Eijsvogels, Thijs M.H., PhD, Januzzi, James L., MD, Taylor, Beth A., PhD, Isaacs, Stephanie K., BS, D'Hemecourt, Pierre, MD, Zaleski, Amanda, MS, Dyer, Sophia, MD, Troyanos, Chris, ATC, Weiner, Rory B., MD, Thompson, Paul D., MD, Baggish, Aaron L., MD
• Format: Article
• Language: English
• Subjects: Adult; Cardiovascular; Cholesterol; Female; Follow-Up Studies; Healthy Volunteers; Heart attacks; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology; Male; Marathons; Metabolic disorders; Middle Aged; Myocardial Ischemia - blood; Myocardial Ischemia - prevention & control; Prognosis; Retrospective Studies; Running - physiology; Statins; Troponin I - blood; Troponin T - blood
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2014.05.047

Marathon running commonly causes a transient elevation of creatine kinase and cardiac troponin I (cTnI). The use of statins before marathon running exacerbates the release of creatine kinase from skeletal muscle, but the effect of statin use on exercise-induced cTnI release is unknown. We therefore measured cTnI concentrations in statin-using (n = 30) and nonstatin-using (n = 41) runners who participated in the 2011 Boston Marathon. All runners provided venous blood samples the day before, within an hour of finishing, and 24 hours after the marathon. cTnI was assessed at each time point via both a contemporary cTnI and high-sensitivity cTnI (hsTnI) assay. Before the marathon, cTnI was detectable in 99% of runners with the use of the hsTnI assay. All participants completed the marathon (finish time: 4:04:09 ± 0:41:10), and none had symptoms of an acute coronary syndrome. cTnI increased in all runners (p